Related Experiment Video
Updated: Jun 17, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.6K
The Utility of Smart Multiple Daily Injection Systems in Intensive Insulin-Treated People With Diabetes: An Italian
Francesco Giorgino1, Riccardo Bonfanti2, Filomena Castaldo3
1Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
Journal of Diabetes Science and Technology
|February 10, 2025
Summary
Smart systems for multiple daily injections (Smart MDI) improve glycemic control and reduce treatment burden in diabetes patients. Further research is needed to compare Smart MDI with other advanced insulin delivery systems.
Area of Science:
- Diabetes Technology
- Endocrinology
- Digital Health
Background:
- Smart systems for multiple daily injections (Smart MDI) integrate continuous glucose monitoring, connected insulin pens, smartphone apps, and cloud storage.
- These systems offer bolus dose suggestions, reminders, and automatic tracking of insulin therapy and glycemic data.
Purpose of the Study:
- To establish expert consensus on the clinical value of Smart MDI.
- To identify critical implementation points for Smart MDI in adult and pediatric diabetes care.
Main Methods:
- A nominal group technique combined with the estimate-talk-estimate approach was used.
- Consensus was achieved among Italian diabetes care experts.
Main Results:
- Smart MDI can improve glycemic profiles through data-driven dose suggestions and insulin-on-board calculations.
- Automatic data sharing enables timely and informed therapeutic recommendations.
- Dose tracking, reminders, and reduced hypoglycemia may enhance treatment adherence.
Conclusions:
- Smart MDI can decrease treatment burden and enhance daily experiences and glycemic outcomes for individuals with type 1 or type 2 diabetes.
- High-quality clinical data comparing Smart MDI with other advanced insulin delivery systems are currently lacking.
- More evidence is required to evaluate the impact of Smart MDI on glycemic and patient-reported outcomes.
Related Concept Videos
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...